Treatment choices and neuropsychological symptoms of a large cohort of early MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 5, 2017
- Accepted in final form January 12, 2018
- First Published March 1, 2018.
Author Disclosures
- Olga von Bismarck, medstudent*,
- Theresa Dankowski, PhD*,
- Björn Ambrosius, PhD,
- Nicole Hessler, Msc,
- Gisela Antony, Dipl-Psych,
- Andreas Ziegler, PhD,
- Muna-Miriam Hoshi, MD,
- Lilian Aly, MD,
- Felix Luessi, MD,
- Sergiu Groppa, MD,
- Luisa Klotz, MD,
- Sven G. Meuth, MD,
- Björn Tackenberg, MD,
- Muriel Stoppe, MD,
- Florian Then Bergh, MD,
- Hayrettin Tumani, MD,
- Tania Kümpfel, MD,
- Martin Stangel, MD,
- Christoph Heesen, MD,
- Brigitte Wildemann, MD,
- Friedemann Paul, MD,
- Antonios Bayas, MD,
- Clemens Warnke, MD,
- Frank Weber, MD,
- Ralf A. Linker, MD,
- Ulf Ziemann, MD,
- Uwe K. Zettl, MD,
- Frauke Zipp, MD,
- Heinz Wiendl, MD,
- Bernhard Hemmer, MD,
- Ralf Gold, MD and
- Anke Salmen, MD
- On behalf of the German Competence Network Multiple Sclerosis (KKNMS)
- Olga von Bismarck, medstudent*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Theresa Dankowski, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Björn Ambrosius, PhD,
NONE
NONE
Commercial, travel grant, 5000? Novartis for AAN 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
FORUM Anschubfinanzierung, Medizinische Faktult?t Ruhr Universit?t Bochum, F?rderkennzeichen: F859-15
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nicole Hessler, Msc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gisela Antony, Dipl-Psych,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) German Ministry of Education and Research, BMBF 01GI1304A, PI "Core Unit IT KKNMS", 2013-2016 (2) German Ministry of Education and Research, BMBF 01GI1601B, PI "Core Unit IT KKNMS", 2016-2019 (3) German Ministry of Education and Research, BMBF 01GM1514C, PI "Core Unit IT Dystonia Network", 2016-2019 (4) EU, EU-FP7-305653, PI "Core Unit IT chILD-EU (European Management Platform for Childhood Interstitial Lung Diseases)", 2016
University Marburg, Leader Central Information Office Competence Network Parkinson, 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andreas Ziegler, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Ministry of Education and Research, 01GI1601G, PI, 2015-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Muna-Miriam Hoshi, MD,
scientific advisory board for Merck Serono
NONE
travel grant from Bayer Health Care
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lilian Aly, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Felix Luessi, MD,
NONE
Travel grants from Teva Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sergiu Groppa, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Klotz, MD,
(1) Genzyme (2) Novartis (3) Biogen
NONE
(1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) CSL Behring, speaker honoraria and travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Biogen
(1) (CRC) SFB TR-128 Impact of dietary factors on the gut-CNS-axis ? implications for CNS autoimmunity A08, Project leader, 2016-2020 (2) (CRC) SFB 1009 ?Immune-cell interactions with endothelial cells and pericytes at the blood-brain- barrier: mechanisms and consequences? A03, Sub-project Leader, 2012-2020 (3) Federal Ministry of Education and Research (BMBF) Competence Network Multiple Sklerose: ?Multi-parameter immune cell-profiling: identification of biosignatures to understand heterogeneity, prognosis and treatment response factors in MS?, 3.1 Sub-project Leader, 2016-2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD,
(1) Almirall (2) Bayer Health Care (3) Biogen (4) Genzyme (5) Merck Serono (6) Novartis (7) Novo Nordisk (8) Roche (9) Sanofi-Aventis (10) Teva (11) Diamed (12) MedDay Pharmaceuticals (13) ONO Pharma
NONE
(1) Almirall, travel or speaker honoraria (2) Bayer Health Care, travel or speaker honoraria (3) Biogen, travel or speaker honoraria (4) Genzyme, travel or speaker honoraria (5) Merck Serono, travel or speaker honoraria (6) Novartis, travel or speaker honoraria (7) Novo Nordisk, travel or speaker honoraria (8) Roche, travel or speaker honoraria (9) Sanofi-Aventis, travel or speaker honoraria (10) Teva, travel or speaker honoraria (11) Diamed, travel or speaker honoraria (12) MedDay Pharmaceuticals, travel or speaker honoraria (13) ONO Pharma
PLoS One
(1)Effectivity of specific FXII/FXIIa inhibitors, particularly rHA-Infestin 4 used to treat neuro- inflammatoral diseases (WO 2013/113774 A1 and EP 2 263 110 A1) (2) Diagnosis of a novel autoimmune disease (European patent; 15001186.4 ? 1402) (3)
NONE
NONE
(1) Almirall (2) Bayer Health Care (3) Biogen (4) Genzyme (5) Merck Serono (6) Novartis (7) Novo Nordisk (8) Roche (9) Sanofi-Aventis (10) Teva (11) Diamed (12) MedDay Pharmaceuticals (13) ONO Pharma
NONE
NONE
NONE
(1) Almirall (2) Bayer Health Care (3) Biogen (4) Genzyme (5) Merck Serono (6) Novartis (7) Novo Nordisk (8) Roche (9) Sanofi-Aventis (10) Teva (11) Diamed (12) MedDay Pharmaceuticals (13) ONO Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Björn Tackenberg, MD,
Served on scientific advisory boards for (1) Biogen-idec Germany and USA, (2) Bayer Healthcare Germany and USA, (3) Novartis Germany, (4) Merck-Serono Germany, (5) Octapharma Germany, (6) CSL Behring Germany, (7) GRIFOLS Germany
NONE
received speaker honoraria from (1) Biogen-idec Germany and USA, (2) Bayer Healthcare Germany and USA, (3) Novartis Germany, (4) Merck-Serono Germany, (5) TEVA Germany, (6) Sanofi-Aventis Germany, (7) Octapharma Germany, (8) CSL Behring Germany, (9) GRIFOLS Germany, (10) GSK Germany
NONE
NONE
NONE
NONE
received Consultancy fees from (1) Biogen-idec Germany and USA, (2) Bayer Healthcare Germany and USA, (3) Novartis Germany, (4) Merck-Serono Germany, (5) Octapharma Germany, (6) CSL Behring Germany, (7) GRIFOLS Germany
NONE
NONE
NONE
(1) Bayer Healthcare Germany, (2) Biogen-idec Germany, (3) Novartis Germany, (4) Sanofi-Aventis Germany
NONE
(1) Marburg University Trust
F?rderverein Neurologie e. V. (FN). German Myasthenia gravis Society (DMG). German Society of Neurology (DGN)
NONE
NONE
NONE
NONE
NONE
NONE
- Muriel Stoppe, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Florian Then Bergh, MD,
Speaker honoraria and consultancy fees as a speaker and advisor from Bayer Healthcare, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Actelion, Novartis, TEVA
German Federal Ministry of Research; Deutsche Forschungsgemeinschaft (DFG, federal research funding agency)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hayrettin Tumani, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tania Kümpfel, MD,
NONE
NONE
I have received travel expenses and personal compensations for lectures from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, CLB Behring, Roche Pharma and Biogen as well as grant support from Bayer-Schering AG, Novartis and Chugai Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Stangel, MD,
Biogen, Baxalta/Shire, CSL Behring, Grifols, MedDay, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Teva
NONE
Travel and speaker honoraria from Bayer Healthcare, Biogen, CSL Behring, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva
PLoS ONE, Academic Editor; Multiple Sclerosis International, Editorial Board Member
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Merck-Serono, Novartis, Sanofi-Genzyme, Teva
Deutsche Forschungsgemeinschaft (DFG), Bundesministerium f?r Bildung und Forschung (BMBF), EU FP7
NONE
Volkswagenstiftung
NONE
NONE
NONE
NONE
NONE
NONE
- Christoph Heesen, MD,
NONE
NONE
Received speaker honoraries from Biogen, Merck, Genyzme, Novartis
International Journal of MS Care, 2014 until now
NONE
NONE
NONE
NONE
NONE
Received Research grants from Genzyme, Biogen, Roche, Novartis, Merck, Roche.
NONE
Genzyme Sanofi Aventis Biogen Novartis Roche
German Minstery of Research, PI 2012-2016 Hertie Foundation, PI 2014-2016
NONE
NMSS
NONE
NONE
NONE
NONE
NONE
NONE
- Brigitte Wildemann, MD,
Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche
NONE
Brigitte Wildemann has received personal fees from Biogen, Merck Serono, Novartis Pharmaceuticals, TEVA Pharma, and from Sanofi Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Brigitte Wildemann reports grants from Bundesministerium f?r Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD,
Novartis OCTIMS study steering committee MedImmune steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Antonios Bayas, MD,
(1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (6) Sanofi/Genzyme (7) Roche
NONE
(1) Merck Serono: travel, speaker honoraria (2) Biogen: travel, speaker honoraria (3) Novartis: travel, speaker honoraria (4) TEVA: travel, speaker honoraria (6) Sanofi/Genzyme: travel, speaker honoraria
NONE
NONE
NONE
NONE
(1) Merck Serono (2) Biogen (3) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Clemens Warnke, MD,
Biogen, Novartis
NONE
Speakers honoraria Novartis, Biogen, Bayer, Teva.
Frontiers in Neurology, associate editor, 2016-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Hertie foundation, Charcot foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Weber, MD,
Genzyme Novartis
NONE
Biogen Speaker honoraria TEVA Speaker honoraria Merck-Serono travel grant Novartis travel grant Pfizer Speaker honoraria
NONE
NONE
NONE
Sana, head of neurological clinic, since 01.01.2018
NONE
NONE
NONE
NONE
Merck-Serono Novartis
BMBF
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf A. Linker, MD,
Biogen, Genzyme, Merck,Novartis, Roche, TEVA.
NONE
Biogen, Genzyme, Merck, Novartis, Roche, TEVA.
NONE
NONE
NONE
NONE
Biogen, Novartis, Roche.
NONE
NONE
NONE
Biogen, Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ulf Ziemann, MD,
(1) CorTec GmbH
NONE
(1) Bayer Vital GmbH, speaker honorarium (2) Biogen Idec GmbH, speaker honorarium (3) Bristol Myers Squibb GmbH, speaker honorarium (4) Medtronic GmbH, speaker honorarium (5) Pfizer Pharma GmbH, speaker honorarium
(1) Clinical Neurophysiology, Editor-in-Chief, 2 years (2) Journal of Neuroscience, Associate Editor, 3 years (3) Brain Stimulation, Deputy Editor, 10 years (4) Experimental Brain Research, Editorial advisory board member, 13 years
NONE
(1) Lehrbuch Neurologie, Elsevier, 2011 (2) Das TMS Buch, Springer, 2007 (3) The Oxford Handbook of Trancranial Stimulation, Oxford University Press, 2007
NONE
NONE
NONE
(1) Biogen Idec GmbH, Investigator initiated trial (2) Janssen Pharmaceuticals NV, Investigator initiated trial (3) Servier, Investigator initiated trial
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Uwe K. Zettl, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Speakers honoraria and travel grants from Bayer Pharma, Aventis Pharma, TEVA Pharma, Merck-Serono Pharma, Biogen-Idec Pharma.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frauke Zipp, MD,
(1)Teva (2) Merck Serono (3) Novartis (4) Bayer Healthcare (5) Biogen Idec Germany (6) ONO (7) Genzyme (8) Sanofi-Aventis (9) Octapharma
NONE
(1)Teva (2) Merck Serono (3) Novartis (4) Bayer Healthcare (5) Biogen Idec Germany (6) ONO (7) Genzyme (8) Sanofi-Aventis (9) Octapharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Teva (2) Merck Serono (3) Novartis (4) Bayer
(1) DFG CRC-TRR 128, Co-Spokesperson/Spokesperson, 2012-2020 (2) DFG CRC1080, PI, 2013-2020 (3) BMBF KKNMS, PI, 2013-2019
NONE
(1) Progressive MS Alliance, BRAVEinMS (2) Patient-Centered Outcomes Research Institute (PCORI), PRAG-MS
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD,
(1) Bayer Healthcare (2) Biogen Idec (3) Sanofi- Genzyme (4) Merck Serono (5) Novartis (6) Roche (7) Teva
NONE
(1) Bayer Vital GmbH (2) Bayer Schering AG (3) Biogen (4) CSL Behring (5) EMD Serono (6) Fresenius Medical Care (7) Sanofi - Genzyme (8) Merck Serono (9) Omniamed (10) Novartis (11) Teva (12) GlaxoSmithKline (13) GW Pharmaceuticals
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Biogen (2) Merck Serono (3) Novartis (4) Omniamed (5) Roche (6) Sanofi-Genzyme
NONE
NONE
NONE
(1) Bayer Healthcare (2) Bayer Vital (3) Biogen (4) Merck Serono (5) Novartis (6) Sanofi ? Genzyme (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kr?ner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children?s Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Bernhard Hemmer, MD,
Advisory Boards for F. Hoffmann-La Roche Ltd, Novartis, Bayer AG, and Genentech; he has served as DMSC member for AllergyCare
Me or my institution have received speaker honoraria from Biogen Idec, Teva Neuroscience, Merck Serono, Medimmune, Novartis, Desitin, Hoffman-LaRoche
Excemed
Editorial board member of Jama Neurology and MS Journal
I hold part of two patents; one for the detection of antibodies a n d T c e l l s a g a i n s t K I R 4 . 1 i n a s u b p o p u l a t i o n o f M S p a t i e n t s a n d o n e f o r g e n e t i c d e t e r m i n a n t s o f neutralizing antibodies to interferon β
NONE
NONE
NONE
NONE
NONE
NONE
Chugai Pharmaceuticals
German Research foundation, German Ministry of Education and Research, EU Horizon 2020, EU IMI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Gold, MD and
(1) TEVA Laquinimod DSMB
NONE
Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering,Ozgene, Novartis
SAGE Journal, Aktuelle Neurologie, Experimental Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anke Salmen, MD
NONE
NONE
speaker honoraria and/or travel compensation for activities with Almirall Hermal GmbH, Biogen, Merck, Novartis, Roche, and Sanofi Genzyme; none related to this work.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (O.v.B., B.A., R.G., A.S.), St. Josef-Hospital, Ruhr-University Bochum; Institute of Medical Biometry and Statistics (T.D., N.H., A.Z.), University of Lübeck, University Hospital Schleswig-Holstein, Campus Lübeck; Central Information Office (CIO) (G.A.), Philipps-University Marburg, Germany; School of Mathematics (A.Z.), Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg, South Africa; Department of Neurology (M.-M.H., L.A., B.H.), Klinikum rechts der Isar, Technical University of Munich; Munich Cluster for Systems Neurology (SyNergy) (L.A., B.H.); Department of Neurology (F.L., S.G., F.Z.), University Medicine Mainz, Johannes Gutenberg University Mainz; Department of Neurology (L.K., S.G.M., H.W.), University Hospital Münster; Department of Neurology (B.T.), Philipps-University Marburg; Department of Neurology (M.Stoppe, F.T.B.), University of Leipzig; Department of Neurology (H.T.), University of Ulm; Clinic of Neurology Dietenbronn (H.T.), Schwendi; Institute of Clinical Neuroimmunology (T.K.), Ludwig Maximilian University of Munich; Department of Neurology (M.Stangel), Hannover Medical School; Institut für Neuroimmunologie und Multiple Sklerose (C.H.), Universitätsklinikum Hamburg-Eppendorf; Department of Neurology (B.W.), University of Heidelberg; NeuroCure Clinical Research Center and Experimental and Clinical Research Center (F.P.), Charité—University Medicine Berlin and Max Delbrueck Center for Molecular Medicine; Department of Neurology (A.B.), Klinikum Augsburg; Department of Neurology (C.W.), Heinrich-Heine-University, Düsseldorf; Department of Neurology (C.W.), University Hospital Köln; Neurology (F.W.), Max-Planck-Institute of Psychiatry, Munich; Neurological Clinic (F.W.), MATERNUS Kliniken AG, Bad Oeynhausen; Department of Neurology (R.A.L.), University Hospital Erlangen; Department of Neurology & Stroke (U.Z.), Hertie Institute for Clinical Brain Research, Eberhard-Karls-University Tübingen; Department of Neurology (U.K.Z.), University of Rostock, Germany; and Department of Neurology (A.S.), Inselspital Bern, University Hospital and University of Bern, Switzerland.
- Correspondence
Dr. Salmen anke.salmen{at}insel.ch
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Responsiveness and predictive value of EDSS and MSFC in primary progressive MSJ. J. Kragt, A. J. Thompson, X. Montalban et al.Neurology, January 09, 2008 -
Articles
The Multiple Sclerosis Functional CompositeA clinically meaningful measure of disabilityChris H. Polman, Richard A. Rudick et al.Neurology, April 26, 2010 -
Research Article
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple SclerosisA Real-world Case SeriesRichard S. Nicholas, Elijah E. Rhone, Alice Mariottini et al.Neurology, July 12, 2021 -
Article
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGavin Giovannoni, Jeffrey A. Cohen, Alasdair J. Coles et al.Neurology, October 12, 2016